Penumbra (NYSE: PEN) and Apollo Endosurgery (NASDAQ:APEN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.
This table compares Penumbra and Apollo Endosurgery’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings for Penumbra and Apollo Endosurgery, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Penumbra currently has a consensus price target of $98.00, suggesting a potential upside of 7.05%. Apollo Endosurgery has a consensus price target of $11.00, suggesting a potential upside of 108.73%. Given Apollo Endosurgery’s higher probable upside, analysts clearly believe Apollo Endosurgery is more favorable than Penumbra.
Institutional & Insider Ownership
70.9% of Penumbra shares are held by institutional investors. Comparatively, 8.9% of Apollo Endosurgery shares are held by institutional investors. 13.5% of Penumbra shares are held by company insiders. Comparatively, 74.2% of Apollo Endosurgery shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Penumbra and Apollo Endosurgery’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Penumbra||$294.09 million||10.51||-$3.32 million||($0.27)||-339.06|
|Apollo Endosurgery||$63.01 million||1.44||-$10.53 million||N/A||N/A|
Penumbra has higher revenue and earnings than Apollo Endosurgery.
Volatility and Risk
Penumbra has a beta of 0.09, meaning that its share price is 91% less volatile than the S&P 500. Comparatively, Apollo Endosurgery has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500.
Penumbra beats Apollo Endosurgery on 7 of the 11 factors compared between the two stocks.
Penumbra, Inc. is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. It focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. Its neuro products include Neurovascular Access, Neuro Thrombectomy (Ischemic Stroke), Neurovascular Embolization (Brain Aneurysms) and Neurosurgical Tools (Hemorrhagic Stroke). Its peripheral vascular products include Peripheral Vascular Embolization and Peripheral Thrombectomy.
About Apollo Endosurgery
Apollo Endosurgery, Inc., formerly Lpath, Inc., is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries. The Company’s products include ORBERA, LAP-BAND and OverStitch. The Company’s product, ORBERA, is a gastric balloon. The ORBERA Intragastric Balloon System is a weight loss aid for adults suffering from obesity. The LAP-BAND System is a minimally invasive procedure that offers weight loss. The LAP-BAND System is indicated for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope. OverStitch offers solutions for defects in both the upper and lower gastrointestinal tract.
What are top analysts saying about Penumbra Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Penumbra Inc. and related companies.